Ultime notizie per VSee Health (NASDAQ:VSEE) Azioni

VSee Health

VSee Health Inc is a telehealth software platform. VSee's telemedicine solution, offering a fast, secure text + video collaboration app HIPAA messenger, and fully customizable virtual waiting rooms and clinics, is a complete telehealth platform that fits into any workflow. The VSee proprietary technology platform and modular software solution enable users to plug and play telehealth services with end-to-end encrypted video streaming integrated with patient metrics, electronic medical records, and other sensitive data, with multiple other interactive functionalities. The company's products include VSee Clinic, VSee Messenger, VSee APIs, VSee Remote patient monitoring, VSee Telehealth Staffing.

VSee Health Inc

Legislative progress on providing veterans with access to <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic therapies</a> like psilocybin, found in magic mushrooms, hit a roadblock last week as Virginia lawmakers decided not to advance a bill aimed at expanding mental health treatments for veterans. 
As Henrico Citizen <a href="https://www.henricocitizen.com/veteran-use-of-psychedelics-for-mental-health-care-still-up-in-the-air/">reported</a>, the bill, introduced by Sen. Ghazala Hashmi (D-Richmond) and Del. Michael Jones (D-Richmond), sought to create an advisory council that would study how breakthrough therapies could be used to help <a href="https://www.benzinga.com/24/11/41881842/why-do-veterans-deserve-access-to-psychedelic-therapy">reduce veteran suicide rates and treat mental health disorders</a>, including post-traumatic stress disorder (PTSD). However, without further action from lawmakers, the bill was left in committee as of November 18, the deadline for bills to be considered from the previous General Assembly session.
<h3 class="wp-block-heading">The Bill</h3>
The <a href="https://lis.virginia.gov/bill-details/20251/HB80?">legislation</a> proposed a deep dive into federal regulations and licensing requirements for breakthrough therapies, which would include substances like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a>. While the bill did not explicitly mention psilocybin, it is recognized as a potential breakthrough therapy due to its promising effects on mental health. Studies, including research from Johns Hopkins Medicine, have found that psilocybin helps alleviate symptoms of depression, anxiety and PTSD, and even aids in smoking cessation.
<h3 class="wp-block-heading">Challenges In Rescheduling Psilocybin For Medicinal Use</h3>
Despite <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">evidence supporting psilocybin&#8217;s therapeutic potential</a>, it remains a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I substance</a> in Virginia, limiting its medical use. In 2023, a <a href="https://legacylis.virginia.gov/cgi-bin/legp604.exe?231+sum+SB932=&amp;">bill</a> to reschedule it to Schedule III failed. This classification is controversial, especially considering fentanyl, another Schedule I drug, is responsible for most overdose deaths in Virginia, while psilocybin has no overdose-related fatalities.
<h3 class="wp-block-heading">Veterans Call For Better Mental Health Care And Treatment Access</h3>
Del. Jones, whose father was a Vietnam War veteran, voiced frustration at the lack of action. "Veterans deserve any form of effective mental health care they need," said Jones, emphasizing that improving mental health support for veterans should be a priority. He stressed the importance of exploring all treatment options for veterans, acknowledging the struggles some face just getting through daily life. "Every day isn't easy for everybody," Jones remarked. "For some people getting up on Thursday morning is hard as hell, and so, how do we soften that burden?"
Veterans have <a href="https://www.benzinga.com/markets/cannabis/24/10/41320243/massachusetts-veterans-advocate-for-psilocybin-legalization-will-voters-support-them">long advocated for the use of psychedelics</a> to address mental health issues, particularly PTSD, which affects a significant portion of those who have served in the military. Army veteran Anthony Mijares shared his personal testimony about the benefits of psilocybin, stating that it helped him overcome depression and reliance on prescription drugs after his military service. "The military trained me to save people, but it failed to train me on how to heal myself," Mijares said during a 2023 testimony in favor of psilocybin legislation.
Read Also:&nbsp;<a href="https://www.benzinga.com/24/11/41881842/why-do-veterans-deserve-access-to-psychedelic-therapy">Veterans Deserve Access To Life-Changing Psychedelics Therapy: A Vital Solution For PTSD And Healing</a>
<h3 class="wp-block-heading">VA Funds Research On Psychedelic Treatments</h3>
In response to mounting interest in psychedelic therapies, the Department of Veterans Affairs announced in January that it <a href="https://www.benzinga.com/markets/cannabis/24/01/36523540/veterans-affairs-after-decades-will-fund-psychedelic-research-for-vets-with-ptsd-and-depression">would fund research into the use of psychedelics</a> like psilocybin to treat PTSD and depression. representing the first such VA-supported research since the 1960s.
<h3 class="wp-block-heading">The Future Of Psychedelic Treatment For Veterans In Virginia</h3>
Despite setbacks at the state level, Jones remains hopeful that future legislative efforts will prioritize veteran mental health and continue to advance research into psychedelic treatments. "We need to be bold," he said, urging that any future administration support scientific research that could improve the lives of veterans.
Whether the issue will resurface in the upcoming legislative session is still uncertain, as neither Jones nor Hashmi have confirmed plans to reintroduce the bill.
Cover image made with AI

Cannabis

Government

News

Psychedelics

Veteran Access To Psychedelic Mental Health Therapies Stalls In Virginia

WIIM

INTC

Intel shares are trading lower. It was recently reported that the company's CHIPS Act grant was cut by over $600 million.

Smart Approaches to Marijuana (SAM), an active prohibitionist group, has denied allegations of improper communications with the Drug Enforcement Administration (DEA) ahead of next week&#8217;s <a href="https://www.benzinga.com/topic/cannabis-rescheduling">cannabis rescheduling</a> hearing.
SAM's Nov. 25 legal response dismissed the claims as unfounded and aimed at distracting from the proceedings, <a href="https://www.marijuanamoment.net/dea-says-it-didnt-conspire-with-anti-marijuana-group-dismissing-allegedly-illegal-talks-as-gossip/">reported</a> Marijuana Moment.
The hearings, scheduled to begin Dec. 2, will explore the Department of Justice's proposed rule to reschedule cannabis from a Schedule I to a Schedule III drug under the Controlled Substances Act (CSA). The proposal follows recommendations from the U.S. Department of Health and Human Services and the Food and Drug Administration.
<h3 class="wp-block-heading">SAM Pushes Back On Collusion Allegations</h3>
The allegations, raised in a <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">joint motion</a> by cannabis company Village Farms International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) and veterans group Hemp for Victory, sought to disqualify SAM and the DEA from participating in the hearings. 
SAM, one of 25 designated participants, countered that the motion was a baseless attempt to smear its reputation.
"This motion is a transparent effort to smear both SAM and the DEA," SAM's lawyers, Patrick F. Philbin and Chase Harrington, wrote. 
Read Also: <a href="https://www.benzinga.com/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">DEA Judge Blocks Researcher&#8217;s Motion In Cannabis Rescheduling Case</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
They argued that the claims amounted to a "sideshow" and urged the DEA's Administrative Law Judge (ALJ) John J. Mulrooney to focus on the substance of the hearing.
While SAM denied any ex parte communications after the May 21 publication of the notice of proposed rulemaking (NPRM), it acknowledged earlier <a href="https://www.benzinga.com/24/11/42173101/dea-denies-allegations-of-unlawful-talks-with-anti-marijuana-group">social media posts</a> by its president, Kevin Sabet, predicting that Attorney General Merrick Garland, rather than DEA Administrator Anne Milgram, would sign the NPRM.
Critics allege that Sabet's May 6 post referencing "confidential sources inside DEA" raises questions about transparency. As for that evidence, SAM's lawyers argued the post was made before the NPRM's issuance.
<h3 class="wp-block-heading">A Related Case</h3>
The same DEA judge leading this case has recently denied the <a href="https://www.benzinga.com/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">request</a> by research company <a href="https://www.benzinga.com/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">MedPharm</a> to participate in the December 2 hearing, citing his limited authority and deferring to the DEA Administrator&#8217;s discretion over participant selection.
MedPharm criticized the exclusion of DEA-licensed marijuana researchers and the inclusion of prohibitionist groups, calling the process biased and undermining its legitimacy. 
Critics worry the imbalance in witness selection could skew the hearing&#8217;s outcomes, despite support from other federal agencies for rescheduling.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/24/11/42173101/dea-denies-allegations-of-unlawful-talks-with-anti-marijuana-group">DEA Denies Allegations Of Colluding With Anti-Marijuana Group While Involved In Cannabis Rescheduling Process</a></li>
</ul>
COVER: AI-Generated image

Regulations

Politics

Markets

Prohibitionist Group Denies Collusion Allegations Ahead Of DEA Cannabis Rescheduling Hearing

Federal Reserve policymakers unanimously decided to reduce interest rates by 25 basis points to a range of 4.5%-4.75% during their November meeting, as they expressed confidence that inflation was moving sustainably toward their 2% target, according to <a href="https://www.benzinga.com/topic/interest-rates">meeting minutes released Wednesday.</a>
Participants highlighted several factors expected to maintain downward pressure on inflation, including diminishing business pricing power, the Fed&#8217;s restrictive monetary policy stance, and well-anchored long-term inflation expectations. 
<h3 class="wp-block-heading">Easing Inflation, But Core Pressures Persist</h3>
The minutes revealed that nearly all participants believed the latest data supported the view that inflation was steadily moderating, albeit with volatility in month-to-month readings. 
Inflation, they noted, had eased significantly from its peak. However, core inflation measures—excluding volatile food and energy prices—remained &#8220;somewhat elevated.&#8221;
Policymakers also discussed upside risks to inflation, including potential disruptions in global supply chains due to geopolitical events, a faster-than-anticipated loosening of financial conditions, unexpectedly robust consumer spending, persistent shelter price increases, and surging insurance costs across health, automotive, and housing sectors.
<h3 class="wp-block-heading">Resilient Economy and Labor Market Underpin Consumer Spending</h3>
Economic data reviewed at the meeting pointed to stronger-than-expected growth in consumer spending and overall economic activity. 
While participants generally agreed that the labor market remained solid, they emphasized the importance of closely monitoring indicators for signs of softening, which could influence the Fed&#8217;s future policy direction.
&#8220;Participants remarked that consumption had been supported by a solid labor market, rising real wages, and elevated household wealth,&#8221; the minutes stated. &nbsp;
<h3 class="wp-block-heading">Diverging Views on Monetary Policy Adjustments</h3>
The minutes also shed light on varying perspectives regarding the Fed&#8217;s next steps. 
While some participants suggested the central bank could pause its easing cycle and hold rates at restrictive levels if inflation remained sticky, others indicated that policy easing could be accelerated if economic conditions weakened, such as a downturn in the labor market or a notable slowdown in economic activity.
&#8220;Many participants observed that uncertainties concerning the level of the neutral rate of interest complicated the assessment of the degree of restrictiveness of monetary policy and, in their view, made it appropriate to reduce policy restraint gradually,&#8221; according to the November minutes. 
<h3 class="wp-block-heading">Market Reactions</h3>
The release of the Fed meeting minutes had little impact on short-term interest rate markets. 
Fed funds futures continued to show a 59% probability of another 25-basis-point rate cut in December, unchanged from market expectations prior to the minutes&#8217; publication.
The U.S. dollar index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), held steady, gaining 0.2% on the day. Meanwhile, Treasury yields saw marginal changes, with the 10-year Treasury yield broadly holding at 4.32%.
The S&amp;P 500 index – tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – also held its marginal session gains, up 0.3%. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42194139/consumer-confidence-hits-2-year-high-as-recession-fears-fade-stock-market-optimism-soars-to-record-high">Consumer Confidence Hits 2-Year High As Recession Fears Fade: Stock Market Optimism Soars To Record High</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Fed Minutes Reveal 'Confidence' In Inflation Reduction, Yet Flag Divergent Views On Interest Rate Path Ahead

Whales with a lot of money to spend have taken a noticeably bullish stance on Constellation Energy.
Looking at options history for Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) we detected 52 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $281,144 and 47, calls, for a total amount of $2,195,419.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $180.0 and $360.0 for Constellation Energy, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Constellation Energy's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Constellation Energy's whale trades within a strike price range from $180.0 to $360.0 in the last 30 days. 
<h3>Constellation Energy Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732649511_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$6.5</td>
<td>$6.3</td>
<td>$6.4</td>
<td>$300.00</td>
<td>$128.0K</td>
<td>4.1K</td>
<td align="right">440</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.0</td>
<td>$5.8</td>
<td>$5.8</td>
<td>$280.00</td>
<td>$115.4K</td>
<td>782</td>
<td align="right">342</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$18.5</td>
<td>$17.2</td>
<td>$17.85</td>
<td>$250.00</td>
<td>$107.6K</td>
<td>859</td>
<td align="right">447</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$21.7</td>
<td>$19.3</td>
<td>$21.0</td>
<td>$210.00</td>
<td>$105.0K</td>
<td>21</td>
<td align="right">50</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$24.3</td>
<td>$22.5</td>
<td>$22.5</td>
<td>$260.00</td>
<td>$101.2K</td>
<td>271</td>
<td align="right">45</td>
</tr>
</tbody>
</table>

<h3>About Constellation Energy</h3>
Constellation Energy Corp offers energy solutions. It provides clean energy and sustainable solutions to homes, businesses, the public sector, community aggregations, and a range of wholesale customers (such as municipalities, cooperatives, and other strategics). The company offers comprehensive energy solutions and a variety of pricing options for electric, natural gas, and renewable energy products for companies of any size.
Following our analysis of the options activities associated with Constellation Energy, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Constellation Energy</h3>
<ul>
<li>Currently trading with a volume of 2,588,934, the CEG's price is up by 5.87%, now at $263.55. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 91 days.</li>
</ul>
<h3>Professional Analyst Ratings for Constellation Energy</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $283.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Constellation Energy with a target price of $270. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Constellation Energy, maintaining a target price of $291. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Constellation Energy, maintaining a target price of $322. 
&#x2A; An analyst from Mizuho persists with their Neutral rating on Constellation Energy, maintaining a target price of $235. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Constellation Energy, which currently sits at a price target of $298. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Constellation Energy, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Constellation Energy's Options: A Look at What the Big Money is Thinking

Deep-pocketed investors have adopted a bullish approach towards Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SAVA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Cassava Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 44% bearish. Among these notable options, 14 are puts, totaling $1,005,809, and 4 are calls, amounting to $358,518.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $2.5 to $50.0 for Cassava Sciences over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cassava Sciences's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cassava Sciences's whale activity within a strike price range from $2.5 to $50.0 in the last 30 days. 
<h3>Cassava Sciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732649506_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.45</td>
<td>$16.3</td>
<td>$16.42</td>
<td>$20.00</td>
<td>$328.3K</td>
<td>2.8K</td>
<td>57</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.6</td>
<td>$1.21</td>
<td>$1.25</td>
<td>$5.00</td>
<td>$234.6K</td>
<td>675</td>
<td>2.0K</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$16.45</td>
<td>$16.3</td>
<td>$16.4</td>
<td>$20.00</td>
<td>$136.1K</td>
<td>2.8K</td>
<td>362</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.0</td>
<td>$13.85</td>
<td>$13.85</td>
<td>$17.50</td>
<td>$74.7K</td>
<td>5.2K</td>
<td>54</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$12.0</td>
<td>$11.5</td>
<td>$12.0</td>
<td>$16.00</td>
<td>$60.0K</td>
<td>103</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Cassava Sciences</h3>
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
In light of the recent options history for Cassava Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Cassava Sciences</h3>
<ul>
<li>With a trading volume of 25,393,267, the price of SAVA is down by -6.4%, reaching $4.02.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 92 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cassava Sciences</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $116.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Neutral, setting a price target of $116. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $116. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cassava Sciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SAVA

Unpacking the Latest Options Trading Trends in Cassava Sciences

Investors with a lot of money to spend have taken a bullish stance on STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with STM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for STMicroelectronics.
This isn't normal.
The overall sentiment of these big-money traders is split between 68% bullish and 31%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $431,012, and 8 are calls, for a total amount of $668,404.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $21.0 and $27.0 for STMicroelectronics, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of STMicroelectronics stands at 573.64, with a total volume reaching 11,435.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in STMicroelectronics, situated within the strike price corridor from $21.0 to $27.0, throughout the last 30 days.
<h3>STMicroelectronics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732649500_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>STM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.9</td>
<td>$5.8</td>
<td>$5.9</td>
<td>$21.00</td>
<td>$156.3K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$22.00</td>
<td>$143.1K</td>
<td align="right">92</td>
<td align="right">265</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$23.00</td>
<td>$111.3K</td>
<td align="right">60</td>
<td align="right">1</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.4</td>
<td>$2.35</td>
<td>$2.35</td>
<td>$24.00</td>
<td>$62.2K</td>
<td align="right">949</td>
<td align="right">270</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.1</td>
<td>$5.9</td>
<td>$6.1</td>
<td>$21.00</td>
<td>$59.7K</td>
<td align="right">2</td>
<td align="right">98</td>
</tr>
</tbody>
</table>

<h3>About STMicroelectronics</h3>
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
After a thorough review of the options trading surrounding STMicroelectronics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of STMicroelectronics</h3>
<ul>
<li>With a trading volume of 3,820,555, the price of STM is up by 1.79%, reaching $26.21.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 58 days from now.</li>
</ul>
<h3>What The Experts Say On STMicroelectronics</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $33.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Craig-Hallum persists with their Buy rating on STMicroelectronics, maintaining a target price of $36. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on STMicroelectronics, maintaining a target price of $33. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on STMicroelectronics, which currently sits at a price target of $30. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on STMicroelectronics, maintaining a target price of $33. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for STMicroelectronics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

STMicroelectronics Unusual Options Activity For November 26

BSFC

Blue Star Foods shares are trading higher after the company announced a $1.5 million buyback program.

Buybacks

Blue Star Foods Announces $1.5M Stock Buyback Program

<a href="https://www.chevron.com/newsroom/2024/q4/new-california-legislation-misleading-chevron-exec-says" title="https://www.chevron.com/newsroom/2024/q4/new-california-legislation-misleading-chevron-exec-says">https://www.chevron.com/newsroom/2024/q4/new-california-legislation-misleading-chevron-exec-says</a>

Chevron Exec Says "Chevron Is Concerned By The Recent Committee And Assembly Passages Of Assembly Bill X2-1"; New California Legislation Can Have Negative Impact On California's Energy Infrastructure

Shares of housing and building-related stocks are trading lower. Building permits and new home sales fell in October.

Mexican President Claudia Sheinbaum offered a sharp rebuke of President-elect Donald Trump&#8216;s <a href="https://www.benzinga.com/topic/tariffs">tariff threats</a>.
What Happened: <a href="https://www.bloomberg.com/news/articles/2024-11-26/mexico-hints-at-retaliation-after-trump-threatens-steep-tariffs?srnd=homepage-americas">According</a> to Bloomberg. Sheinbaum has suggested that Mexico could respond to U.S. tariffs with a protectionist policy of its own.
"One tariff will be followed by another in response, and so on until we put common companies at risk," Sheinbaum said at a press conference. "The main exporters from Mexico to the US are General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), and Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), which arrived 80 years ago. Why put in place a tariff that puts them at risk?"
Why It Matters: Retaliatory action could put the two allied countries in a trade war. 
Trump <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42194139/consumer-confidence-hits-2-year-high-as-recession-fears-fade-stock-market-optimism-soars-to-record-high">announced</a> that he would put a 25% tariff against Mexico and Canada on his first day in office in retaliation for illegal border crossings into the U.S. 
Trump also said it was in response to fentanyl trafficking. But the policy would hurt the Big Three automakers, which have roots in Detroit, Michigan. 
The U.S.-based auto manufacturers have slumped in recent quarters; all three traded well in the red on Tuesday after Trump&#8217;s announcement. Tariffs on automobiles would likely leave Americans paying more for cars.
Mexican stocks also performed poorly on Tuesday; the iShares MSCI Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) traded down over 3% following Trump&#8217;s announcement.
Trump ally Bill Ackman seemed to not take the President-elect at his word. The billionaire hedge fund manager suggested the tariffs are <a href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns">&#8220;a weapon&#8221;</a> and won&#8217;t be implemented. 
Trump did implement tariffs against China during his first term; the Tax Foundation later <a href="https://taxfoundation.org/research/all/federal/tariffs/">estimated</a> that Americans incurred $80 billion in taxes from the tariffs.
Republican megadonor and Citadel CEO Ken Griffin has a <a href="https://www.benzinga.com/news/global/24/11/42056528/gop-megadonor-ken-griffin-warns-of-slippery-slope-in-trumps-tariff-plans-sees-us-returning-to-the-business-of-business">less favorable view</a> of Trump&#8217;s policy, calling tariffs a &#8220;slippery slope&#8221; that will hurt U.S. companies.
Most economists say tariffs are regressive taxes that disproportionately hurt poor Americans while stifling economic growth. Trump&#8217;s adoption of pro-tariff policies is a stark contrast to the free trade policies championed by Republican President Ronald Reagan during the 1980s.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42194139/consumer-confidence-hits-2-year-high-as-recession-fears-fade-stock-market-optimism-soars-to-record-high">Consumer Confidence Hits 2-Year High As Recession Fears Fade: Stock Market Optimism Soars To Record High</a></li>
</ul>
Image: Shutterstock

Global

STLA

Will Trump Lead US Into Trade War With Mexico? President Claudia Sheinbaum Rebukes Threats

For almost two years now, stocks that tap into the global $15.7 trillion AI revolution have surged so quickly, the media has a nickname for them: the "Magnificent Seven."
But there's a problem with the "Magnificent Seven"—the dividends that they offer investors are extremely stingy, as management prefers to devote hundreds of billions of dollars towards research and development.
Apple Inc. (AAPL), for instance, pays a dividend of just 0.5%. Microsoft Inc. (MSFT)'s dividend of 0.95% is well below the S&amp;P 500 average of 1.29%. Nvidia Inc. (NVDA) pays just&nbsp; 0.03% dividend yield—not a typo—and Tesla Motors (TSLA) and Alphabet (GOOG) pay nothing at all.
But there's a little-known way to claim much bigger quarterly payouts from the AI revolution—thanks to three companies that collect billions of dollars in "rent" from the Magnificent Seven.
AI Income Machine No. 1: Prologis Inc. (PLD)
Headquartered in San Francisco, California, Prologis Inc. (PLD) is a real estate investment trust that leases over 1.2 billion square feet worldwide to some of the world's biggest names, including Amazon.
The company's business of leasing office and retail space to various tech firms is so lucrative, it has a profit margin of 37.4% as of Q3/2024. For context, Apple has a profit margin of 24%.
Not only that, but PLD is growing earnings at a robust clip. The company grew earnings by 34.5% last quarter, and was able to raise its dividend by 10.3% in 2024.
Since 2019, PLD has nearly doubled its dividend while increasing payouts every year. It now offers a 3.2% dividend yield that is more than double the S&amp;P 500… and larger than the yields of all the "Magnificent Seven" stocks combined.
AI Income Machine No. 2: Alexandria Real Estate Inc. (ARE)
Headquartered in Pasadena, California, Alexandria Real Estate Inc. (ARE) is a company that leases 47 million square feet of office and retail space to companies in San Francisco, Boston, New York City, Austin, Seattle, and Washington D.C.
ARE has grown operating income by 299% since 2014—and it's no accident that its rise has been strongly correlated with the tech boom that's unfolded since.
ARE's string of lucrative deals in the tech sector contributed to its monster earnings growth of 592% last quarter—and helped it increase its dividend by 29% since 2019.
Alexandria Real Estate pays a yield of 4.8% as of this writing, which thrashes the average company on the S&amp;P 500 and, like PLD, is a higher yield than that of all the Magnificent Seven companies combined.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout-black-friday-24/?utm_source=WebRD-1126">[For Even More stock Picks! Benzinga Edge Black Friday Savings Start Now!]</a>
AI Income Machine No. 3: Digital Realty Trust (DLR)
As AI processors continue to demand ungodly amounts of power around the world, Digital Realty trust's modular designs to accommodate advanced cooling solutions are in strong demand.
DLR is a real estate investment trust that counts tech giants like Oracle, IBM, Meta, and LinkedIn among its clients—and by leasing property to these deep-pocketed titans, it has built a cash-gushing empire around the globe.
In fact, DLR now has a backlog of $859 billion, as tech giants jostle to use its global data center platform. The company has grown its dividend by 15% since 2019, and offers a 2.57% yield that is highly likely to grow in the years ahead.
Get the tools you need to stay ahead—daily trade setups, exclusive stock picks, and real-time alerts. Don't miss out on Benzinga Edge at 75% off. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout-black-friday-24/?utm_source=WebRD-1126">Join today for the best deal of the year!</a>
Image via Pexels

Opinion

Trading Ideas

3 "AI Income Machines" Leaving the Magnificent Seven in the Dust

Cheating complaints are piling up in <a href="https://www.benzinga.com/general/gaming/24/10/41662426/black-ops-6-shatters-records-call-of-dutys-biggest-launch-drives-60-sales-spike">Call of Duty: Black Ops 6</a> just days after the launch of its ranked multiplayer mode on Nov. 21. 
Activision responded with details about its anti-cheat efforts, but players are voicing frustration over what they see as persistent issues undermining the game's competitive integrity.
<h1 class="wp-block-heading">Activision Responds To Cheating Concerns</h1>
In a recent tweet, Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Activision said its anti-cheat team, Team Ricochet, is conducting "hourly sweeps" to remove cheaters from ranked play and leaderboards. The company reported over 19,000 account bans since the mode went live and announced improvements to its <a href="https://www.benzinga.com/general/gaming/24/10/41435803/activisions-new-ai-strategy-aims-to-ban-call-of-duty-cheaters-within-one-hour-of-their-first-match">AI systems to speed up enforcement.</a>
See Also: <a href="https://www.benzinga.com/24/11/42145982/call-of-duty-black-ops-6-leads-video-game-october-sales-in-the-us">Call Of Duty: Black Ops 6 Leads Video Game October Sales In The US</a>
"Thanks for your patience as our team continues to fight against cheaters," the tweet stated.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f4e2; <a href="https://twitter.com/hashtag/BlackOps6?src=hash&amp;ref_src=twsrc%5Etfw">#BlackOps6</a> <a href="https://twitter.com/hashtag/RankedPlay?src=hash&amp;ref_src=twsrc%5Etfw">#RankedPlay</a> <a href="https://twitter.com/hashtag/TeamRICOCHET?src=hash&amp;ref_src=twsrc%5Etfw">#TeamRICOCHET</a> with an update on the ongoing work to combat cheating in Ranked Play: • AI systems continue to ramp up with code optimizations to accelerate enforcements • Over 19,000 Ranked Play bans since the mode launched • Hourly sweeps to remove…
&mdash; Call of Duty Updates (@CODUpdates) <a href="https://twitter.com/CODUpdates/status/1861241515798098184?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite these claims, skepticism has been widespread among the community. Nadeshot, founder of 100 Thieves, took to social media to criticize the company, calling the statement "complete propaganda."
"I have played the same cheaters since day one and not a single one has even a scratch on ‘em," he tweeted. "How could there possibly be 19K accounts banned when the most egregious abusers are giving us the middle finger on the leaderboard? Are we crazy? What is going on?"
<h1 class="wp-block-heading">A Longstanding Problem For Activision</h1>
Cheating has been a thorn in the side of the Call of Duty franchise for years, especially since the explosive popularity of Warzone in 2020. Activision has poured resources into combating the issue, from introducing the<a href="https://www.benzinga.com/general/gaming/24/01/36664783/activision-alerts-call-of-duty-players-anti-cheat-tech-will-ban-aim-assist-ranked-play-will-face-d"> Ricochet anti-cheat </a>system to taking legal action against cheat developers.
Before Black Ops 6 launched, Activision promised faster detection and removal of cheaters, aiming to remove offenders within an hour of their first match. Ricochet's kernel-level driver, paired with machine-learning systems, was designed to detect and neutralize cheats such as aim bots more effectively.
"The people behind cheats are organized, illegal groups that pick apart every piece of data within our games to look for some way to make cheating possible," Activision said in a statement last month. "These bad guys are not just some script kiddies poking around with code they found online. They are a collective who profit from exploiting the hard work of game developers across the industry."
Despite these measures, ranked play has already become another battleground for cheaters, prompting many console players to disable crossplay to avoid PC opponents.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42118521/xbox-cloud-gaming-now-lets-you-stream-owned-games-heres-how-it-works">Xbox Cloud Gaming Now Lets You Stream Owned Games: Here&#8217;s How It Works</a></li>
</ul>
Photo: Shutterstock.

Gaming

General

MSFT

19,000 Bans And Counting, But Players Say Cheating Still Dominates Call Of Duty Black Ops 6

Whales with a lot of money to spend have taken a noticeably bullish stance on Soleno Therapeutics.
Looking at options history for Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $265,110 and 6, calls, for a total amount of $523,533.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $70.0 for Soleno Therapeutics over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Soleno Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Soleno Therapeutics's whale trades within a strike price range from $40.0 to $70.0 in the last 30 days. 
<h3>Soleno Therapeutics Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732648603_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLNO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.3</td>
<td>$0.75</td>
<td>$0.8</td>
<td>$65.00</td>
<td>$202.7K</td>
<td>2.5K</td>
<td>2.5K</td>
</tr>
<tr>
<td>SLNO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.0</td>
<td>$0.25</td>
<td>$0.3</td>
<td>$40.00</td>
<td>$133.4K</td>
<td>35.6K</td>
<td>4.5K</td>
</tr>
<tr>
<td>SLNO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.1</td>
<td>$2.4</td>
<td>$2.9</td>
<td>$55.00</td>
<td>$129.3K</td>
<td>1.7K</td>
<td>701</td>
</tr>
<tr>
<td>SLNO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$7.5</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$70.00</td>
<td>$95.2K</td>
<td>79</td>
<td>69</td>
</tr>
<tr>
<td>SLNO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$55.00</td>
<td>$76.8K</td>
<td>162</td>
<td>262</td>
</tr>
</tbody>
</table>

<h3>About Soleno Therapeutics</h3>
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Having examined the options trading patterns of Soleno Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Soleno Therapeutics</h3>
<ul>
<li>Currently trading with a volume of 1,138,044, the SLNO's price is up by 1.58%, now at $58.12. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 99 days.</li>
</ul>
<h3>Professional Analyst Ratings for Soleno Therapeutics</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $71.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Soleno Therapeutics, which currently sits at a price target of $73. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $70.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Soleno Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

SLNO

What the Options Market Tells Us About Soleno Therapeutics

Investors with a lot of money to spend have taken a bearish stance on Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MTCH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Match Group.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 62%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $128,046, and 6 are calls, for a total amount of $205,266.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $33.0 to $36.5 for Match Group over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Match Group options trades today is 316.33 with a total volume of 11,531.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Match Group's big money trades within a strike price range of $33.0 to $36.5 over the last 30 days.
<h3>Match Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732648598_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTCH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$35.00</td>
<td>$66.8K</td>
<td align="right">930</td>
<td>164</td>
</tr>
<tr>
<td>MTCH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.55</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$36.50</td>
<td>$61.2K</td>
<td align="right">0</td>
<td>153</td>
</tr>
<tr>
<td>MTCH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$1.01</td>
<td>$0.85</td>
<td>$0.9</td>
<td>$33.00</td>
<td>$45.6K</td>
<td align="right">19</td>
<td>1.4K</td>
</tr>
<tr>
<td>MTCH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$0.9</td>
<td>$0.82</td>
<td>$0.84</td>
<td>$33.00</td>
<td>$38.4K</td>
<td align="right">19</td>
<td>3.1K</td>
</tr>
<tr>
<td>MTCH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/13/24</td>
<td>$1.01</td>
<td>$0.84</td>
<td>$0.9</td>
<td>$33.00</td>
<td>$35.6K</td>
<td align="right">19</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Match Group</h3>
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Hinge, BLK, Chispa, Match.com, OkCupid, PlentyOfFish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
After a thorough review of the options trading surrounding Match Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Match Group</h3>
<ul>
<li>Currently trading with a volume of 1,592,089, the MTCH's price is down by 0.0%, now at $32.57. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 63 days.</li>
</ul>
<h3>What The Experts Say On Match Group</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $38.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Match Group, which currently sits at a price target of $33. 
&#x2A; An analyst from Truist Securities has decided to maintain their Hold rating on Match Group, which currently sits at a price target of $35. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Match Group with a target price of $35. 
&#x2A; Reflecting concerns, an analyst from B of A Securities lowers its rating to Neutral with a new price target of $35. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Match Group, maintaining a target price of $53. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Match Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MTCH

Looking At Match Group's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNOW usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 63 extraordinary options activities for Snowflake. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 46% bearish. Among these notable options, 20 are puts, totaling $2,084,721, and 43 are calls, amounting to $3,056,613.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $230.0 for Snowflake, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Snowflake options trades today is 2009.72 with a total volume of 27,599.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Snowflake's big money trades within a strike price range of $90.0 to $230.0 over the last 30 days.
<h3>Snowflake Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732648593_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.05</td>
<td>$29.75</td>
<td>$30.0</td>
<td>$175.00</td>
<td>$900.0K</td>
<td>680</td>
<td align="right">316</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$23.85</td>
<td>$23.55</td>
<td>$23.79</td>
<td>$165.00</td>
<td>$475.8K</td>
<td>1.4K</td>
<td align="right">203</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$33.95</td>
<td>$33.7</td>
<td>$33.7</td>
<td>$140.00</td>
<td>$316.7K</td>
<td>746</td>
<td align="right">119</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.4</td>
<td>$21.15</td>
<td>$21.3</td>
<td>$170.00</td>
<td>$213.0K</td>
<td>9.6K</td>
<td align="right">669</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$26.15</td>
<td>$25.75</td>
<td>$26.05</td>
<td>$190.00</td>
<td>$197.9K</td>
<td>90</td>
<td align="right">313</td>
</tr>
</tbody>
</table>

<h3>About Snowflake</h3>
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.
After a thorough review of the options trading surrounding Snowflake, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Snowflake's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 5,432,893, the SNOW's price is up by 1.18%, now at $173.45. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 92 days.</li>
</ul>
<h3>What The Experts Say On Snowflake</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $167.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wedbush has decided to maintain their Neutral rating on Snowflake, which currently sits at a price target of $160. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Snowflake with a target price of $150. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Snowflake, which currently sits at a price target of $150. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Snowflake, which currently sits at a price target of $180. 
&#x2A; An analyst from Mizuho persists with their Outperform rating on Snowflake, maintaining a target price of $195. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Snowflake with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

SNOW

Snowflake Unusual Options Activity

U.S. stocks traded mostly higher toward the end of trading, with the S&amp;P 500 gaining around 0.5% on Tuesday.
The Dow traded up 0.05% to 44,759.66 while the NASDAQ rose 0.59% to 19,166.93. The S&amp;P 500 also rose, gaining, 0.47% to 6,015.37.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a>
Leading and Lagging Sectors Utilities shares jumped by 1.1% on Tuesday.
In trading on Tuesday, materials shares fell by 0.7%.
Top Headline
Dick's Sporting Goods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) reported upbeat earnings for its third quarter.
The company posted third-quarter adjusted earnings per share of $2.75, beating the street view of $2.68. Quarterly sales of $3.06 billion (+0.5%) outpaced the analyst consensus of $3.03 billion.
Dick's Sporting now expects FY24 earnings per share to be between $13.65 and $13.95, up from the previous forecast of $13.55 to $13.90, compared to the consensus estimate of $13.88. The company sees FY24 net sales of $13.2 billion to $13.3 billion versus the $13.25 billion consensus and the prior view of $13.1 billion to 13.2 billion
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares shot up 226% to $9.32 after the company announced it will be acquired by Roche in a $1.5 billion deal, with stockholders receiving up to $13 per share in cash.</li>
<li>Shares of Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) got a boost, surging 64% to $7.78 after the company reported better-than-expected third-quarter sales results.</li>
<li>Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) shares were also up, gaining 33% to $19.13 after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Alector, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) shares dropped 35% to $2.5650 after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer&#8217;s disease failed to meet its primary endpoint.</li>
<li>Shares of Leslie&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) were down 33% to $2.37 after the company reported worse-than-expected quarterly adjusted EPS and sales.</li>
<li>Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) was down, falling 17% to $15.20 after the company reported worse-than-expected third-quarter results, cut its FY24 EPS guidance, and projected a net sales decrease of 7%-8%.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $68.49 while gold traded up 0.3% at $2,626.70.
Silver traded up 0.9% to $30.510 on Tuesday, while copper fell 1% to $4.1160.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 slipped 0.57%, Germany's DAX fell 0.56% and France's CAC 40 slipped 0.87%. Spain's IBEX 35 Index fell 0.80%, while London's FTSE 100 fell 0.40%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 falling 0.87%, Hong Kong's Hang Seng Index gaining 0.04%, China's Shanghai Composite Index falling 0.12% and India's BSE Sensex falling 0.13%.
Hong Kong&#8217;s trade deficit widened to $31 billion in October from $25.8 billion in the year-ago month.
Economics
<ul>
<li>The FHFA house price index rose by 0.7% from the previous month for September.</li>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 4.6% year-over-year in September versus a 5.2% increase in August.</li>
<li>U.S. building permits declined by 0.4% to an annual rate of 1.419 million in October.</li>
<li>Sales of new single-family homes in the U.S. dipped by 17.3% to an annualized rate of 610,000 in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42189449/how-to-earn-500-a-month-from-dell-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Dell Stock Ahead Of Q3 Earnings</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

ALEC

EMBC

HSAI

LESL

PSTX

Crude Oil Moves Lower; Dick's Sporting Goods Earnings Top Views

CPRI

Capri Holdings shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy.

<a href="https://www.federalreserve.gov/monetarypolicy/files/fomcminutes20241107.pdf" title="https://www.federalreserve.gov/monetarypolicy/files/fomcminutes20241107.pdf">https://www.federalreserve.gov/monetarypolicy/files/fomcminutes20241107.pdf</a>

FOMC Minutes Say Many Participants Saw Risk Of Excessive Cooling In Job Market As Having Diminished Somewhat Since September Meeting; Fed Staff Forecast Called For Economic Conditions To Remain Solid, As In Previous Assessment; 2024 GDP Growth Projection Is Seen As Higher

VSee Health receives Nasdaq notice regarding delayed Form 10-Q filing

The latest announcement is out from VSee Health ( ($VSEE) ). VSee Health, Inc. is facing compliance issues after failing to file its quarterly fina...

VSee Health Faces Nasdaq Compliance Challenges

VSee Health GAAP EPS of -$0.06, revenue of $1.71M

VSee Health ( ($VSEE) ) has shared an update. VSee Health, Inc. is making waves in the telehealth industry with its comprehensive security-focused ...

VSee Health Co-CEO Speaks on Telehealth Innovation and Security

VSee Health ( ($VSEE) ) has issued an announcement. VSee Health, in partnership with the Kwajalein Atoll Government and Sustainability Laboratory, ...

VSee Health Launches Telehealth Initiative for Remote Areas

VSee Health ( ($VSEE) ) has provided an announcement. VSee Health, Inc. has launched a new telehealth initiative integrating GLP-1 prescription med...

VSee Health Launches Affordable Telehealth Initiative

VSee Health ( ($VSEE) ) has provided an update. VSee Health and BabyLiveAdvice have joined forces to tackle the maternal care crisis in the U.S. by...

VSee Health Partners with BabyLiveAdvice for Maternal Care

VSee Health reports Q3 results

An announcement from VSee Health ( ($VSEE) ) is now available. VSee Health, Health Tech Without Borders, and iDocta are expanding their Project VIT...

VSee Health Expands Telehealth Pilot in Cameroon

VSee Health ( ($VSEE) ) has shared an update. VSee Health and The TeleDentists have joined forces to launch the first virtual oral health complianc...

Comments

VSee Health

Notizie

Ultime notizie per VSee Health (NASDAQ:VSEE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO